JP7308816B2 - ビスアミド筋節活性化化合物及びその使用 - Google Patents

ビスアミド筋節活性化化合物及びその使用 Download PDF

Info

Publication number
JP7308816B2
JP7308816B2 JP2020514579A JP2020514579A JP7308816B2 JP 7308816 B2 JP7308816 B2 JP 7308816B2 JP 2020514579 A JP2020514579 A JP 2020514579A JP 2020514579 A JP2020514579 A JP 2020514579A JP 7308816 B2 JP7308816 B2 JP 7308816B2
Authority
JP
Japan
Prior art keywords
carbonyl
trifluoromethyl
methyl
prolinamide
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020514579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533347A5 (OSRAM
JP2020533347A (ja
Inventor
アシュクラフト，ルーク
ボエツィオ，アレッサンドロ
バトラー，ジョン
チャンドラ，アループ
チャン，チユエン
コリービー，スコット・イー
デベネデト，ミッケル
ディマッサ，ビンセント
グラセッファ，ラッセル
マリノフスキ，ジャスティン
メビウス，デビッド
モーガン，ブラッドリー・ピー
ペイエット，ジョシュア
ロメロ，アントニオ
サン・ジャン，デビッド，ジュニア
バルガス，リチャード
ヨーマン，ジョン
チャン，ハンモ
チェン，アラン
ゴンザレス・ロペス・デ・トゥリソ，フェリクス
ジョンソン，マイケル・ギャレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of JP2020533347A publication Critical patent/JP2020533347A/ja
Publication of JP2020533347A5 publication Critical patent/JP2020533347A5/ja
Application granted granted Critical
Publication of JP7308816B2 publication Critical patent/JP7308816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020514579A 2017-09-13 2018-09-13 ビスアミド筋節活性化化合物及びその使用 Active JP7308816B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557846P 2017-09-13 2017-09-13
US62/557,846 2017-09-13
PCT/US2018/050793 WO2019055590A1 (en) 2017-09-13 2018-09-13 SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2020533347A JP2020533347A (ja) 2020-11-19
JP2020533347A5 JP2020533347A5 (OSRAM) 2021-10-21
JP7308816B2 true JP7308816B2 (ja) 2023-07-14

Family

ID=63794635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514579A Active JP7308816B2 (ja) 2017-09-13 2018-09-13 ビスアミド筋節活性化化合物及びその使用

Country Status (24)

Country Link
US (6) US10723720B2 (OSRAM)
EP (1) EP3681882A1 (OSRAM)
JP (1) JP7308816B2 (OSRAM)
KR (1) KR20200054237A (OSRAM)
CN (1) CN111601798B (OSRAM)
AR (1) AR112804A1 (OSRAM)
AU (1) AU2018332887B2 (OSRAM)
BR (1) BR112020004800A2 (OSRAM)
CA (1) CA3075669A1 (OSRAM)
CL (1) CL2020000610A1 (OSRAM)
CO (1) CO2020002745A2 (OSRAM)
CR (1) CR20200116A (OSRAM)
EA (1) EA202090688A1 (OSRAM)
IL (1) IL272573B2 (OSRAM)
JO (1) JOP20200059A1 (OSRAM)
MA (1) MA50173A (OSRAM)
MX (2) MX2020002696A (OSRAM)
PE (1) PE20200924A1 (OSRAM)
PH (1) PH12020500446A1 (OSRAM)
SA (1) SA520411524B1 (OSRAM)
SG (1) SG11202001377PA (OSRAM)
TW (1) TWI790281B (OSRAM)
UY (1) UY37879A (OSRAM)
WO (1) WO2019055590A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022524609A (ja) * 2019-03-12 2022-05-09 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形及び共結晶
JP2022525102A (ja) * 2019-03-12 2022-05-11 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018332887B2 (en) 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
KR20210016545A (ko) * 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
BR112022000915A2 (pt) * 2019-07-23 2022-05-17 Bayer Ag Compostos de heteroaril-triazol como pesticidas
JP7721142B2 (ja) 2019-12-04 2025-08-12 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CA3159172A1 (en) 2019-12-04 2021-06-10 Michael Cicirelli Masp-2 inhibitors and methods of use
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
IL293551A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
CA3182633A1 (en) * 2020-06-17 2021-12-23 Ashok Arasappan 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CA3179181A1 (en) * 2021-03-15 2022-09-22 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
WO2023122325A2 (en) * 2021-12-23 2023-06-29 Regents Of The University Of Michigan Meta anilide compounds and methods for use of the same to treat diseases and disorders
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523234A (ja) 2003-03-27 2006-10-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
US20140356322A1 (en) 2012-01-12 2014-12-04 Yale University Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
US5952307A (en) 1994-01-21 1999-09-14 Georgia Tech Research Corp. Basic α-aminoalkylphosphonate derivatives
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
GB9708119D0 (en) 1997-04-22 1997-06-11 Glaxo Group Ltd Chemical compounds
AU1082901A (en) 1999-10-18 2001-04-30 National Jewish Medical And Research Center Method for modulation of cell phenotype
WO2001054506A1 (en) 2000-01-28 2001-08-02 Akkadix Corporation Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
WO2002046419A2 (en) 2000-11-07 2002-06-13 Board Of Regents, The University Of Texas System Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
EP1503986B1 (en) 2001-12-21 2015-09-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
AU2002365057A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
WO2004094610A2 (en) 2003-04-21 2004-11-04 Baylor College Of Medicine Wnt as a factor for cardiac myogenesis
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
JP2005298628A (ja) 2004-04-09 2005-10-27 Sumitomo Chemical Co Ltd オレフィン重合触媒成分及びオレフィン重合体の製造方法
AU2005264988B2 (en) 2004-06-17 2011-09-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
WO2007089805A2 (en) 2006-01-31 2007-08-09 The General Hospital Corporation Anti-hypertrophic effects and inotropic effects of picot
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
CN104024249A (zh) 2011-10-17 2014-09-03 埃南塔制药公司 丙型肝炎病毒抑制剂
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
SI3247707T1 (sl) 2015-01-22 2023-10-30 MyoKardia, Inc. S 4-metilsulfonilom substituirane spojine piperidina sečnine, uporabne za zdravljenje srčnih motenj, kot je dilatacijska kardiomiopatija (dcm)
CA2979070A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
KR20160108281A (ko) 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
SG10202111790YA (en) 2017-06-30 2021-12-30 Amgen Inc Synthesis of omecamtiv mecarbil
AU2018332887B2 (en) 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
WO2020037164A1 (en) 2018-08-17 2020-02-20 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
JP2022525102A (ja) 2019-03-12 2022-05-11 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形
KR20220002885A (ko) 2019-03-12 2022-01-07 암젠 인크 심장 트로포닌 활성제의 다형체 및 공결정

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523234A (ja) 2003-03-27 2006-10-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
US20140356322A1 (en) 2012-01-12 2014-12-04 Yale University Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CAS Registry No. 1097658-50-8，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2009年01月29日
CAS Registry No. 1213997-94-4，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2010年03月24日
CAS Registry No. 1214678-55-3，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2020年03月25日
CAS Registry No. 1277022-79-3，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2011年04月08日
CAS Registry No. 1277084-61-3，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2011年04月08日
CAS Registry No. 1286423-54-8，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2011年04月27日
CAS Registry No. 1315622-99-1，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2011年08月10日
CAS Registry No. 1315749-93-3，DATABASE REGISTRY [online], Retrieved from STN，Entered STN:，2011年08月11日
CAS Registry No. 1315892-01-3，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2011年08月11日
CAS Registry No. 1372039-53-6，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2012年05月01日
CAS Registry No. 333428-59-4，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2001年04月30日
CAS Registry No. 333428-64-1，DATABASE REGISTRY [online], Retrieved from STN，Entered STN，2001年04月30日
GUYLAINE CUNY; ET AL，JOURNAL OF THE AMERICAN CHEMICAL SOCIETY，2004年11月，126(44)，14475 - 14484，http://dx.doi.org/10.1021/ja047472o

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022524609A (ja) * 2019-03-12 2022-05-09 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形及び共結晶
JP2022525102A (ja) * 2019-03-12 2022-05-11 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形

Also Published As

Publication number Publication date
TW201920096A (zh) 2019-06-01
SA520411524B1 (ar) 2024-03-14
MA50173A (fr) 2020-07-29
UY37879A (es) 2019-03-29
IL272573B2 (en) 2023-10-01
SG11202001377PA (en) 2020-03-30
EA202090688A1 (ru) 2020-07-06
US20200223830A1 (en) 2020-07-16
JOP20200059A1 (ar) 2020-03-12
CL2020000610A1 (es) 2020-11-13
CN111601798A (zh) 2020-08-28
MX2022014864A (es) 2022-12-15
US20190077793A1 (en) 2019-03-14
PE20200924A1 (es) 2020-09-14
CR20200116A (es) 2021-04-28
AR112804A1 (es) 2019-12-11
MX2020002696A (es) 2020-09-25
US20200223829A1 (en) 2020-07-16
CN111601798B (zh) 2023-08-11
AU2018332887A1 (en) 2020-02-27
US11299479B1 (en) 2022-04-12
WO2019055590A1 (en) 2019-03-21
US11254658B2 (en) 2022-02-22
IL272573A (en) 2020-03-31
CA3075669A1 (en) 2019-03-21
PH12020500446A1 (en) 2020-11-09
US11780826B2 (en) 2023-10-10
US10899746B2 (en) 2021-01-26
US20240158372A1 (en) 2024-05-16
US20220281850A1 (en) 2022-09-08
KR20200054237A (ko) 2020-05-19
CO2020002745A2 (es) 2020-06-19
BR112020004800A2 (pt) 2020-09-24
IL272573B1 (en) 2023-06-01
AU2018332887B2 (en) 2022-12-08
TWI790281B (zh) 2023-01-21
US10723720B2 (en) 2020-07-28
EP3681882A1 (en) 2020-07-22
JP2020533347A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
JP7308816B2 (ja) ビスアミド筋節活性化化合物及びその使用
CN115298170B (zh) 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物
CN111377917B (zh) 杂环类化合物、中间体、其制备方法及应用
CN104926808B (zh) 二氢嘧啶类化合物及其在药物中的应用
EP3121164B1 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10508104B2 (en) 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
HK1210030A1 (en) Sulfamoyl-aryamides and the use thereof as medicaments for the treatment of hepatitis b
CN105658646A (zh) 作为激酶抑制剂的氨基杂芳基苯甲酰胺
AU2020204341B2 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
IL273839B (en) Benzimidazole derivatives and their uses
IL279482B1 (en) Thiophene derivatives for the treatment of disorders caused by ige
CN118119613A (zh) 作为il-17调节剂的苯并咪唑
EA042825B1 (ru) Бисамидные соединения, активирующие саркомер, и варианты их применения
HK40034269B (zh) 双酰胺肌节活化化合物及其用途
HK40034269A (en) Bisamide sarcomere activating compounds and uses thereof
WO2013014627A1 (en) Pyrazoline derivatives and their use as selective androgen receptor modulators
TW202342060A (zh) Ｌｏｎｐ１抑制劑化合物、用途及方法
EA049631B1 (ru) Имидазопиридазины в качестве модуляторов il-17

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230704

R150 Certificate of patent or registration of utility model

Ref document number: 7308816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150